Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OmnicellMEX:OMCL 76 Return-on-Tangible-Asset is 4.41% as of Mar. 2026, which is 37% above its 10-year median of 3.23. GuruFocus rates MEX:OMCL with a GF Score™ of 76/100 and a GF Value™ of MXN630.45. The stock has 8 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Omnicell ranks worse than 52.86% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Omnicell's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN819 Mil. Omnicell's average total tangible assets for the quarter that ended in Mar. 2026 was MXN18,567 Mil. Therefore, Omnicell's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 4.41%.
The historical rank and industry rank for Omnicell's Return-on-Tangible-Asset or its related term are showing as below:
MEX:OMCL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.72 Med: 3.23 Max: 9.9
Current: 1.89
During the past 13 years, Omnicell's highest Return-on-Tangible-Asset was 9.90%. The lowest was -1.72%. And the median was 3.23%.
MEX:OMCL's Return-on-Tangible-Asset is ranked worse than 52.86% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs MEX:OMCL: 1.89
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Omnicell Return-on-Tangible-Asset Related Terms
Omnicell Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Omnicell's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:OMCL vs TDOC, SDGR, OMDA: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Omnicell's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omnicell Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Omnicell's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.41% mean?
Omnicell (MEX:OMCL) has a Return-on-Tangible-Asset of 4.41% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Omnicell and its competitors. This is 37% above median its historical median of 3.23. According to the industry distribution chart, Omnicell ranks #361 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 52.9%.
Is Omnicell's Return-on-Tangible-Asset too high?
Omnicell's current Return-on-Tangible-Asset of 4.41% is 37% above median its 10-year median of 3.23. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.43. Omnicell's value of 4.41% is 81.5% above this industry median. Based on the distribution chart, Omnicell ranks #361 out of 683 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Omnicell has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's Return-on-Tangible-Asset compare to TDOC and SDGR?
According to the Healthcare Providers & Services industry distribution chart, Omnicell ranks #361 out of 683 companies for Return-on-Tangible-Asset. This places Omnicell in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.43. Omnicell's value of 4.41% is 81.5% above this benchmark. While the company's 10-year median is 3.23 vs. the industry median of 2.43, Omnicell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omnicell's current Return-on-Tangible-Asset of 4.41% is 81.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Omnicell and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omnicell's current Return-on-Tangible-Asset is 4.41%, which is 37% above median its own 10-year median of 3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (MEX:OMCL) has a current Return-on-Tangible-Asset of 4.41%. The stock's GF Value™ is MXN630.45, compared to a current price of MXN761.16 — trading 20.7% above its estimated fair value. The current Return-on-Tangible-Asset is 4.41%, which is 37% above median its 10-year median of 3.23 and 81.5% above the Healthcare Providers & Services industry median of 2.43. Omnicell's overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Omnicell (MEX:OMCL), the current Return-on-Tangible-Asset is 4.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omnicell (MEX:OMCL) Overvalued in 2026?
Based on GuruFocus' analysis, Omnicell stock appears to be overvalued.
The current stock price of MXN761.16 is trading 20.7% above its estimated GF Value™ of MXN630.45.
Key valuation signals for MEX:OMCL:
Return-on-Tangible-Asset: 4.41% (37% above median its 10-year median of 3.23)
GF Value™: MXN630.45 vs. price of MXN761.16 (20.7% above fair value)
Industry Position: 81.5% above the Healthcare Providers & Services median (#361 of 683)
No single metric tells the full story. See the MEX:OMCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
76GF Score
Get the complete analysis for MEX:OMCL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:OMCL has been successfully added to your 
